Sigma Planning Corp’s Ligand Pharmaceuticals LGND Stock Holding History

Sigma Planning Corp’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$898K	Buy	4,500 +1,500	+50%	+$297K	0.03%	606
2025 Q4	$567K	Buy	+3,000	New	+$576K	0.02%	746
2019 Q2	–	Sell	-2,970	Closed	-$233K	–	1026
2019 Q1	$233K	Buy	+2,970	New	+$225K	0.01%	781
2018 Q4	–	Sell	-2,106	Closed	-$361K	–	915
2018 Q3	$361K	Buy	+2,106	New	+$318K	0.02%	611

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Sigma Planning Corp's LGND Position: Q1 2026 in Review

Sigma Planning Corp increased its Ligand Pharmaceuticals (LGND) stake by 50% in Q1 2026, buying an estimated $297K and bringing the position to 4,500 shares worth $898K. The position accounts for 0.03% of the portfolio, ranked #606.

Sigma Planning Corp first reported a position in LGND in Q3 2018 and has held it in 4 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

Sigma Planning Corp held 4,500 shares of Ligand Pharmaceuticals worth $898K as of Q1 2026.
Sigma Planning Corp bought 1,500 Ligand Pharmaceuticals shares in Q1 2026, an estimated $297K.
Ligand Pharmaceuticals made up 0.03% of Sigma Planning Corp's portfolio in Q1 2026, its #606 holding.
Sigma Planning Corp first reported a position in Ligand Pharmaceuticals in Q3 2018 and has held it in 4 quarters since.
357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Sigma Planning Corp's 13F filing for Q1 2026, filed 4 May 2026.